Combination Encorafenib Plus Binimetinib in Patients With Melanoma
Platinum-Based Chemo Doublets: Backbone for NSCLC Treatment
Dr. Rizvi on Nivolumab Plus Erlotinib in Patients with EGFR MT NSCLC
Heroes of Chemistry winner Merck & Co Inc.: Rich Tillyer presenting the story behind Zepatier®
Micro-dose chemo for cancer using oncolytic viruses. Cancer therapy - future healthcare
Pembrolizumab is a humanized antibody used in cancer immunotherapy. It is an IgG4 isotype antibody that blocks a protective mechanism of cancer cells, and allows the immune system to destroy those cancer cells. It targets the programmed cell death 1 (PD-1) receptor of lymphocytes. The FDA initially approved it to treat metastatic melanoma. In 2017 the FDA approved it for any unresectable or metastatic solid tumor with certain genetic anomalies. It was the first time the FDA had approved a cancer drug based on tumor genetics rather than tissue type or tumor site.